Risks of diabetics fasting during Ramadan: Hypoglycemia rates with insulin pump v. injections

April 7, 2017
Credit: Mary Ann Liebert, Inc., publishers

A new study examining the risk of fasting during Ramadan for people with type 1 diabetes compared blood glucose control and the rates of hypoglycemia and hyperglycemia between users of insulin pump therapy versus multiple daily insulin injections. The researchers report their findings in Diabetes Technology & Therapeutics (DTT).

Reem Alamoudi, MD, MHSc, Imam Abdulrahman Bin Faisal National Guard Hospital, Dammam, Saudi Arabia, and coauthors from Saudi Arabia and Qatar compared glucose data collected using self-monitoring or continuous glucose monitoring in two groups of , one on a regimen of daily insulin injections and the other using continuous subcutaneous infusion.

In the article entitled "Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting," the researchers highlight the differences in glucose control, glucose variability, and rates of hypo- and hyper-glycemia between the two treatment groups. Hypoglycemia is common among patients with type 1 diabetes who fast during Ramadan and is the main cause of having to break the fast.

"In the future, use of an 'artificial pancreas' hybrid closed-loop system during Ramadan may allow patients to reduce or even eliminate hypoglycemia with increased time-in-range and reduced variability," says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora).

Explore further: Lowest glucose variability for insulin + GLP-1 RA in T2DM

More information: Reem Alamoudi et al, Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting, Diabetes Technology & Therapeutics (2017). DOI: 10.1089/dia.2016.0418

Related Stories

Lowest glucose variability for insulin + GLP-1 RA in T2DM

December 20, 2016

(HealthDay)—For patients with type 2 diabetes, the lowest glucose variability (GV) and hypoglycemia is seen for patients using basal insulin + glucagon-like peptide 1 receptor agonist (GLP-1 RA) (BGLP), according to a study ...

Recommended for you

Many diabetes patients produce some insulin

June 22, 2017

Some insulin is still produced in almost half of patients that have had type 1 diabetes for more than ten years. The study conducted by researchers at Uppsala University in Sweden has now been published online by the medical ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.